CoDa Therapeutics

CoDa CEO Bradford J. Duft

The biotech: CoDa Therapeutics
Round: $19.4 million
Based: San Diego
CEO: Bradford J. Duft
Investors: RusNano

The scoop: When Domain Associates announced earlier this year that it had struck up a close partnership with RusNano to help the Russian fund identify new investment opportunities, it may well have had CoDa in mind. Domain had already invested $20 million in CoDa's Series B, and the Russians would double down with another $20 million. CoDa's focus is on its Nexagon topical gel, which it boasts will help speed healing of diabetic foot ulcers and other wounds. The new deal with the Russians will call for some extra attention on that market, where RusNano is shepherding a fledgling biopharma industry. Also, it's the first of a number of new biotech investments expected from RusNano, which is finding plenty of places to place its bets.

For more:
Rusnano, Domain team top up CoDa venture round with $20M
CoDa banks $19M round for mid-stage wound healing study

CoDa Therapeutics

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.